PDL BioPharma (PDLI) Misses Q4 EPS by 25c

PDL BioPharma (NASDAQ: PDLI) reported Q4 EPS of $0.32, $0.25 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $117.1 million versus the consensus estimate of $158.15 million.

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping withdraws bid to acquire Genco Shipping
• Vivos Therapeutics posts 35% revenue gain but widens net loss